Vaccination as a therapeutic approach to Alzheimer's disease

Mount Sinai Journal of Medicine

Volumn 77, Issue 1, 2010, Pages 17-31

  Wisniewski, Thomas ^a   Boutajangout, Allal ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Immunomodulation; Tau; Transgenic mice; Vaccination

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; FREUND ADJUVANT; IMMUNOGLOBULIN; POLYSORBATE 80; QS 21; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG WITHDRAWAL; ENCEPHALITIS; FAMILIAL DISEASE; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PAIRED HELICAL FILAMENT; PASSIVE IMMUNIZATION; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; TAU PROTEINS; VACCINATION;

EID: 75649143681     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20156     Document Type: Review

References (164)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-191.
2. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009; 7: 7.
3. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative diseases. Annu Rev Neurosci 2008; 31: 175-193.
4. Wisniewski T, Konietzko U. Amyloid-â immunization for Alzheimer's disease. Lancet Neurol 2008; 7: 805-811.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
6. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120: 545-555.
7. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006; 52: 3-13.
8. Lemere CA, Blusztajn JK, Yamaguchi H, et al. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16-32.
9. Gotz J, Chen F, van DJ, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-1495.
10. Oddo S, Caccamo A, Shepherd JD, et al. Tripletransgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
11. King ME, Kan HM, Baas PW, et al. Tau-dependent microtubule disassembly initiated by prefibrillar betaamyloid. J Cell Biol 2006; 175: 541-546.
12. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 1999; 400: 173-177.
13. Sigurdsson EM, Scholtzova H, Mehta P, et al. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 2001; 159: 439-447.
14. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2001; 408: 982-985.
15. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
16. Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006; 281: 1599-1604.
17. Blurton-Jones M, LaFerla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 2006; 3: 437-448.
18. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: 225-236.
19. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.
20. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
21. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral betaamyloidogenesis is governed by agent and host. Science 2006; 313: 1781-1784.
22. Holmes C, Boche D, Wilkinson D, et al. Long term effects of Aβ42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function. Lancet 2008; 372: 216-223.
23. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-542.
24. Castellani RJ, Lee HG, Zhu X, et al. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol 2008; 67: 523-531.
25. Shioi J, Georgakopoulos A, Mehta P, et al. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J Neurochem 2007; 101: 674-681.
26. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by sitedirected mAb. Proc Natl Acad Sci U S A 1997; 94: 4109-4112.
27. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Investig Drugs 2007; 8: 519-524.
28. Sigurdsson EM, Knudsen EL, Asuni A, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-βderivatives. J Neurosci 2004; 24: 6277-6282.
29. Asuni A, Boutajangout A, Scholtzova H, et al. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur J Neurosci 2006; 24: 2530-2542.
30. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
31. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855.
32. Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 2001; 20: 705-711.
33. Sigurdsson EM, Scholtzova H, Mehta P, et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 2001; 159: 439-447.
34. Sigurdsson EM, Frangione B, Wisniewski T. Immunization for Alzheimer's disease. Drug Dev Res 2002; 56: 135-142.
35. Wisniewski T, Frangione B. Immunological and antichaperone therapeutic approaches for Alzheimer's disease. Brain Pathol 2005; 15: 72-77.
36. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ 42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
37. Pride M, Seubert P, Grundman M, et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008; 5: 194-196.
38. Wisniewski T. Practice point commentary on "Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial." Nat Clin Pract Neurol 2005; 1: 84-85.
39. Boche D, Nicoll JA. The role of the immune system in clearance of Abeta from the brain. Brain Pathol 2008; 18: 267-278.
40. Bombois S, Maurage CA, Gompel M, et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 2007; 64: 583-587.
41. Ferrer I, Boada RM, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
42. Masliah E, Hansen L, Adame A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131.
43. Nicoll JA,Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2005; 9: 448-452.
44. Nicoll JA, Barton E, Boche D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006; 65: 1040-1048.
45. Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Curr Pharm Des 2007; 13: 1943-1954.
46. Hock C, Konietzko U, Straffer JR, et al. Antibodies against â-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
47. Hock C, Konietzko U, Paspassotiropoulos A, et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-1276.
48. Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
49. Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30: 1728-1736.
50. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002; 298: 1379.
51. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunization against Abeta in aged APPtransgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm 2004; 1: 24.
52. Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-636.
53. Wilcock DM, Jantzen PT, Li Q, et al. Amyloidbeta vaccination, but not nitro-nonsteroidal antiinflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007; 144: 950-960.
54. Petrushina I, Ghochikyan A, Mkrtichyan M, et al. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflamm 2008; 5: 42.
55. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-836.
56. Zhang-Nunes SX, Maat-Schieman ML, Van Duinen SG, et al. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006; 16: 30-39.
57. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15: 157-168.
58. Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 2009; 3: 78-83.
59. Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009; 21: 359-363.
60. Goedert M, Wischik CM, Crowther RA, et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 1988; 85: 4051-4055.
61. Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3: 519-526.
62. Utton MA, Noble WJ, Hill JE, et al. Molecular motors implicated in the axonal transport of tau and alphasynuclein. J Cell Sci 2005; 118: 4645-4654.
63. Magnani E, Fan J, Gasparini L, et al. Interaction of tau protein with the dynactin complex. EMBO J 2007; 26: 4546-4554.
64. Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 2009; 4: 13.
65. Morishima-Kawashima M, Hasegawa M, Takio K, et al. Hyperphosphorylation of tau in PHF. Neurobiol Aging 1995; 16: 365-371.
66. Sergeant N, David JP, Lefranc D, et al. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett 1997; 412: 578-582.
67. Butner KA, Kirschner MW. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 1991; 115: 717-730.
68. Brion JP, Flament-Durand J, Dustin P. Alzheimer's disease and tau proteins. Lancet 1986; 2: 1098.
69. Brion JP. Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease. J Alzheimers Dis 2006; 9: 177-185.
70. Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008; 85: 148-175.
71. Boutajangout A, Boom A, Leroy K, Brion JP. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS Lett 2004; 576: 183-189.
72. Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
73. Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008; 5: 207-224.
74. Baumann K, Mandelkow EM, Biernat J, et al. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 1993; 336: 417-424.
75. Hamdane M, Sambo AV, Delobel P, et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 2003; 278: 34 026-34 034.
76. Gotz J, Barmettler R, Ferrari A, et al. In vivo analysis of wild-type and FTDP-17 tau transgenic mice. Ann N Y Acad Sci 2000; 920: 126-133.
77. Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276: 529-534.
78. Gotz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9: 532-544.
79. Lewis J, Dickson D, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
80. Ishihara T, Zhang B, Higuchi K, et al. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am J Pathol 2001; 158: 555-562.
81. Tanemura K, Akagi T, Murayama M, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 2001; 8: 1036-1045.
82. Egashira N, Iwasaki K, Takashima A, et al. Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res 2005; 1059: 7-12.
83. Lee VM, Kenyon TK, Trojanowski JQ. Transgenic animal models of tauopathies. Biochim Biophys Acta 2005; 1739: 251-259.
84. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-351.
85. Murakami T, Paitel E, Kawarabayashi T, et al. Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. Am J Pathol 2006; 169: 1365-1375.
86. Taniguchi T, Doe N, Matsuyama S, et al. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett 2005; 579: 5704-5712.
87. Zilka N, Korenova M, Novak M. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol 2009; 118: 71-86.
88. Andorfer C, Kress Y, Espinoza M, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86: 582-590.
89. Andorfer C, Acker CM, Kress Y, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005; 25: 5446-5454.
90. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-9129.
91. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 2009; 6: 446-450.
92. Eidenmuller J, Fath T, Maas T, et al. Phosphorylationmimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J 2001; 357: 759-767.
93. Fath T, Eidenmuller J, Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 2002; 22: 9733-9741.
94. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-868.
95. Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282: 18 895-18 906.
96. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12 845-12 852.
97. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913.
98. Ren PH, Lauckner JE, Kachirskaia I, et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 219-225.
99. Aguzzi A. Cell biology: beyond the prion principle. Nature 2009; 459: 924-925.
100. Sadowski M, Verma A, Wisniewski T. Infectious disease of the nervous system: prion diseases. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. Neurology in Clinical Practice. Philadelphia, PA: Elsevier; 2008:; 1567-1581.
101. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
102. Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009; 8: 144-159.
103. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
104. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36: 811-822.
105. Sigurdsson EM, Wadghiri YZ, Mosconi L, et al. A nontoxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging 2008; 29: 836-877.
106. Scholtzova H, Wadghiri YZ, Douadi M, et al. A NMDA receptor antagonist leads to behavioral improvement and amyloid reduction in Alzheimer's disease model transgenic mice shown by micro-magnetic resonance imaging. J Neurosci Res 2008; 86: 2784-2791.
107. Rowe CC, Ng S, Ackermann U, et al. Imaging betaamyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
108. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465.
109. Roher AE, Kokjohn TA. Of mice and men: the relevance of transgenic mice Abeta immunizations to Alzheimer's disease. J Alzheimers Dis 2002; 4: 431-434.
110. Tenner AJ, Fonseca MI. The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. Adv Exp Med Biol 2006; 586: 153-176.
111. Gandy S, DeMattos RB, Lemere CA, et al. Alzheimer's Aβ vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004; 18: 44-46.
112. Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165: 283-297.
113. Trouche SG, Asuni A, Rouland S, et al. Antibody response and plasma Aβ 1-40 in young Microcebus murinus primates immunized with Aβ 1-42 and its derivatives. Vaccine 2009; 27: 957-964.
114. Gandy S, DeMattos RB, Lemere CA, et al. Alzheimer's Aβ vaccination of rhesus monkeys (Macaca mulatta). Mech Ageing Dev 2004; 125: 149-151.
115. Lemere CA, Iglesias M, Spooner ET, et al. Aβ immunization in aged vervet monkeys reduces Aβ levels in brain and CSF. Soc Neurosci Abstr 2003; 133: 5.
116. Lemere CA, Maier M, Jiang L, et al. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 2006; 9: 77-84.
117. Vasilevko V, Head E. Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle. CNS Neurol Disord Drug Targets 2009; 8: 98-113.
118. Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis 2008; 15: 685-707.
119. Head E, Pop V, Vasilevko V, et al. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008; 28: 3555-3566.
120. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15: 505-514.
121. Maier M, Seabrook TJ, Lazo ND, et al. Short amyloidbeta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006; 26: 4717-4728.
122. Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-1586.
123. Zamora E, Handisurya A, Shafti-Keramat S, et al. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol 2006; 177: 2662-2670.
124. Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006; 24: 6321-6331.
125. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008; 389: 521-536.
126. Movsesyan N, Ghochikyan A, Mkrtichyan M, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS One 2008; 3: e2124.
127. Lemere CA, Spooner ET, Leverone JF, et al. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002; 23: 991-1000.
128. Seabrook TJ, Thomas K, Jiang L, et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 2007; 28: 813-823.
129. Nikolic WV, Bai Y, Obregon D, et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A 2007; 104: 2507-2512.
130. Frackowiak J, Wisniewski HM, Wegiel J, et al. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol 1992; 84: 225-233.
131. Jucker M, Heppner FL. Cerebral and peripheral amyloid phagocytes-an old liaison with a new twist. Neuron 2008; 59: 8-10.
132. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci 2007; 26: 413-416.
133. El KJ, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007; 13: 432-438.
134. Scholtzova H, Kascsak RJ, Bates KA, et al. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J Neurosci 2009; 29: 1846-1854.
135. Tahara K, Kim HD, Jin JJ, et al. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006; 129: 3006-3019.
136. Obregon D, Hou H, Bai Y, et al. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis 2008; 29: 336-353.
137. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. NatMed 2008; 14: 681-687.
138. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283: 29 639-29 643.
139. Klybin I, Betts V, Blennow K, et al. Aβ dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008; 28: 4231-4237.
140. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloidbeta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281: 4292-4299.
141. Moretto N, Bolchi A, Rivetti C, et al. Conformationsensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 2007; 282: 11 436-11 445.
142. Mamikonyan G, Necula M, Mkrtichyan M, et al. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 2007; 282: 22 376-22 386.
143. Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007; 100: 23-35.
144. Lambert MP, Velasco PT, Viola KL, Klein WL. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets 2009; 8: 65-81.
145. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14 537-14 545.
146. Giuffrida ML, Caraci F, Pignataro B, et al. Betaamyloid monomers are neuroprotective. J Neurosci 2009; 29: 10 582-10 587.
147. Wisniewski T, Prelli F, Scholtzova H, et al. Immunotherapy targeting abnormal protein conformation. Alzheimers Dement 2009; 4: 113.
148. Wisniewski T, Sigurdsson EM. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J 2007; 274: 3784-3798.
149. Goni F, Prelli F, Schreiber F, et al. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neuroscience 2008; 153: 679-686.
150. Gotz J, Probst A, Spillantini MG, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995; 14: 1304-1313.
151. Probst A, Gotz J, Wiederhold KH, et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 2000; 99: 469-481.
152. Spittaels K, Van den HC, Van Dorpe J, et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999; 155: 2153-2165.
153. Brion JP, Tremp G, Octave JN. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol 1999; 154: 255-270.
154. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24: 751-762.
155. Higuchi M, Ishihara T, Zhang B, et al. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 2002; 35: 433-446.
156. Boutajangout A, Leroy K, Touchet N, et al. Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett 2002; 318: 29-33.
157. Boutajangout A, Authelet M, Blanchard V, et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol Dis 2004; 15: 47-60.
158. Terwel D, Lasrado R, Snauwaert J, et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 2005; 280: 3963-3973.
159. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25: 402-405.
160. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22: 9340-9351.
161. Gotz J, Tolnay M, Barmettler R, et al. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci 2001; 13: 2131-2140.
162. Tatebayashi Y, Miyasaka T, Chui DH, et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A 2002; 99: 13 896-13 901.
163. Lim F, Hernandez F, Lucas JJ, et al. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol Cell Neurosci 2001; 18: 702-714.
164. Schindowski K, Bretteville A, Leroy K, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169: 599-616.